<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550949</url>
  </required_header>
  <id_info>
    <org_study_id>QL1206-003</org_study_id>
    <nct_id>NCT04550949</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva® in Patients With Bone Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blind, comparative study to evaluate the clinical efficacy&#xD;
      and safety of QL1206 and Xgeva® in patients with bone metastases from solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is A multi-center, randomized, double-blind, comparative clinical trial.&#xD;
&#xD;
      The primary objective is to evaluate whether the clinical efficacy of QL1206 and Xgeva® are&#xD;
      similar in patients with bone metastases from solid tumors.&#xD;
&#xD;
      The secondary objective are to evaluate whether the clinical safety and immunogenicity of&#xD;
      QL1206 and Xgeva® are similar in patients with bone metastases from solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">June 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uNTx/uCr</measure>
    <time_frame>from baseline to week 13</time_frame>
    <description>Compare QL1206 and Xgeva® for percentage change in bone conversion index (BTM) - urinary type I collagen cross-linked peptide (uNTx) adjusted for urinary creatinine (uCr) in Chinese subjects with solid tumor bone metastasis (uNTx/uCr from baseline to week 13)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uNTx/uCr</measure>
    <time_frame>from baseline to weeks 25 and 53</time_frame>
    <description>Compare the percentage change in QL1206 and Xgeva® for bone conversion indicator uNTx/uCr among subjects with solid tumor metastasis (from baseline to weeks 25 and 53).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-BALP</measure>
    <time_frame>from baseline to weeks 13, 25, and 53</time_frame>
    <description>Compare the changes of bone specific alkaline phosphatase (S-BALP) from baseline to weeks 13, 25, and 53.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRE</measure>
    <time_frame>from baseline to weeks 53</time_frame>
    <description>SRE occurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>QL1206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QL1206 injection(120mg)was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xgeva®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QL1206</intervention_name>
    <description>The active ingredient of QL1206 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.</description>
    <arm_group_label>QL1206</arm_group_label>
    <other_name>recombinant human anti-RANKL monoclonal antibody injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xgeva</intervention_name>
    <description>The active ingredient of Xgeva® is denosumab,subcutaneous injection of 120 mg (1.7ml)every 4 weeks for a maximum of 13 consecutive doses throughout the trial.</description>
    <arm_group_label>Xgeva®</arm_group_label>
    <other_name>Denosumab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Through the explanation of the researcher or the researcher's authorized&#xD;
             representative, the subject has understood the nature and purpose of the study, as&#xD;
             well as the research procedure, and the subject has signed the written informed&#xD;
             consent;&#xD;
&#xD;
          2. Radiologic evidence (i.e. X-ray examination, computed tomography CT, magnetic&#xD;
             resonance imaging MRI, positron emission computed tomography PET-CT) in grade III&#xD;
             grade A hospitals has been documented (within 3 months prior to study administration)&#xD;
             that there is at least one bone metastasis;&#xD;
&#xD;
          3. The ECOG score was 0-2.&#xD;
&#xD;
          4. Chinese adults with solid tumor confirmed by histological or cytological examination&#xD;
             (age ≥18 years, ≤80 years).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who had received any kind of intravenous or oral bisphosphonates before&#xD;
             administration of the first study drug (those who had previously used an intravenous&#xD;
             or oral bisphosphonates but had a continuous use time of less than 3 months and more&#xD;
             than 5 years before the administration of this study could be included in the study).&#xD;
&#xD;
          2. Previous treatment with denosumab.&#xD;
&#xD;
          3. Previous or ongoing osteomyelitis or osteonecrosis of the jaw ONJ , active dental&#xD;
             disease or jaw bone disease requiring oral surgery, the wound of dental operation or&#xD;
             oral surgery has not healed well, or invasive dental operation has been planned during&#xD;
             the study period.&#xD;
&#xD;
          4. Plan to perform radiotherapy or or bone surgery. Patients who received radiotherapy&#xD;
             within one month before the first study drug administration were not allowed to be&#xD;
             included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huiping LI, professor</last_name>
      <phone>010-88140650</phone>
      <email>huipingli2012@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li ZHANG, professor</last_name>
      <phone>020-87342288</phone>
      <email>zhangli@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 19, 2020</last_update_submitted>
  <last_update_submitted_qc>September 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

